ReviewCNS & neurological disorders drug targets2026
Nanoparticle-Based Approaches for Glioblastoma Treatment: Advances and Future Prospects.
Review in CNS & neurological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CNS diseases have recently received a lot of focus. Glioblastoma multiforme (GBM) has the worst prognosis among various cancers. With its aggressive nature and potential for recurrence, GBM is a major concern in neuroscience. Radiotherapy, chemotherapy, and surgical removal are currently employed methods for treating GBM. The blood-brain barrier (BBB) is a major obstacle to effective medication delivery into the central nervous system (CNS), which is a major concern in the treatment of GBM. Nanotechnology helps transport active chemicals to brain tissue, a major glioma treatment challenge. Technology advancements in nanotechnology have the potential to facilitate the trans-BBB delivery of medicinal medications to the central nervous system. To treat illnesses associated with the central nervous system (CNS), it is possible to manage several types of nanoparticles (Nps). Novel therapeutic approaches are being explored, with NPs attracting interest as a potential tool for the targeted eradication of brain tumours. The review article reviewed the relevant literature on the utilisation of NPs for the treatment of Glioblastoma. The articles were obtained through various databases, including ScienceDirect, Scopus, PubMed and Google Scholar. It studies current treatment strategies for Glioblastoma, different NPs treating GBM with their mechanism by crossing the BBB, and various relevant patents of NPs drug delivery were analysed. This review article collects data about various nanoparticles used in GBM, with their mechanism of action. This review discusses the role of nanoparticulate systems in the effective treatment of GBM. It can be concluded from the literature that therapeutic agents can be delivered into the central nervous system through the blood-brain barrier with the use of nanotechnology, and so can be effectively used for the management of GBM.
Indexed as
Identifiers
40993928What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.